Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
Active, not recruiting · Phase 1 · NCT04277637
Conditions: Mature B-Cell Malignancies
At a glance
- Research payments reported, 2025
- $10.6M
- U.S. investigators named
- 13
- Sites paid
- 17
- Planned or actual enrollment
- 437
About the trial
- Sponsor
- BeOne Medicines
- Tested
- Sonrotoclax (drug), Zanubrutinib (drug), Obinutuzumab (drug)
- Dates
- Started 2020-03-24; completion 2027-05-31
- Results posted
- Not yet
The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.
From ClinicalTrials.gov, last updated 2026-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $10.6M in research payments for this study in 2025 (275 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Herbert A. Eradat, M.D., M.S. Internal Medicine · Los Angeles, CA
- Shuo Ma, M.D., PH.D. Hematology & Oncology · Chicago, IL
- Marc S. Hoffmann, MD Hematology & Oncology · Overland Park, KS
- Jacob D. Soumerai, MD Hematology & Oncology · Boston, MA
- Paul J. Hampel, M.D. Hematology · Rochester, MN
- Christopher R. D'angelo, M.D. Hematology · Omaha, NE
- Lori A. Leslie, M.D. Medical Oncology · Hackensack, NJ
- Nicole Lamanna, MD Medical Oncology · New York, NY
- Andrew D. Zelenetz, MD Medical Oncology · New York, NY
- David A. Bond, MD Hematology · Columbus, OH
- Jingzhou Hou Hematology & Oncology · Pittsburgh, PA
- Jan A. Burger, M.D. Internal Medicine · Houston, TX
- Mazyar Shadman, MD,MPH Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Massachusetts General Hospital, MA $1.8M
- Fred Hutchinson Cancer Center $1.3M
- Northwestern University $1.2M
- University of Kansas Medical Center Research Institute, Inc. $1.2M
- Northwestern Memorial Hospital, IL $1.2M
- UPMC Cancer Centers $1.1M
- Mayo Clinic Scottsdale $696,818
- The Ohio State University Dba: Comprehensive Canc $385,812
- Nebraska Medicine $345,840
- Milstein Hospital $282,960
- Ut MD Anderson Cancer Center $232,527
- Hackensack University Medical Center, NJ $200,659
- Memorial Sloan Kettering Cancer Center $186,140
- Dana Farber Mass General Brigham Cancer Care Inc $172,485
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $141,480
- University of Nebraska $99,696
- Ronald Reagan UCLA Medical Center, CA $51,971
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.